Serum S100B and CTLA-4 as Diagnostic and Immunoregulatory Biomarkers in Vitiligo Patients
Medical Science Journal for Advance Research · 19.06.2026 · 7 (2)
DOI: 10.46966/msjar.v7i2.413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Journal for Advance Research, online erschienen am 19.06.2026. Verfasst von Haider Chyad Lafta AL-Janahi und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vitiligo is an acquired autoimmune depigmenting disease in which melanocyte damage, inflammatory amplification and defective immune tolerance interact. The Aim: This study evaluated serum S100B and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as diagnostic and immunoregulatory biomarkers in vitiligo.
Methods
A case-control study included 60 patients with vitiligo and 60 apparently healthy controls. Serum S100B, CTLA-4, IL-10, IL-17 and TGF-beta were measured by ELISA, while CD4, CD8, CD25, CD27 and FoxP3 were assessed by flow cytometry. Group comparisons, receiver operating characteristic (ROC) analysis and correlation testing were performed.
Results
Serum S100B was significantly higher in patients than controls (0.960 +/- 0.06 vs. 0.508 +/- 0.11, P
Zitieren
APA
AL-Janahi, H. C. L., & Dheeb, I. A. (2026). Serum S100B and CTLA-4 as Diagnostic and Immunoregulatory Biomarkers in Vitiligo Patients. Medical Science Journal for Advance Research, 7(2). https://doi.org/10.46966/msjar.v7i2.413
Vancouver
AL-Janahi HCL, Dheeb IA. Serum S100B and CTLA-4 as Diagnostic and Immunoregulatory Biomarkers in Vitiligo Patients. Medical Science Journal for Advance Research. 2026;7(2). doi:10.46966/msjar.v7i2.413
BibTeX
@article{ALJanahi2026,
author = {AL-Janahi, Haider Chyad Lafta and Dheeb, Israa Abdulwahid},
title = {Serum S100B and CTLA-4 as Diagnostic and Immunoregulatory Biomarkers in Vitiligo Patients},
journal = {Medical Science Journal for Advance Research},
year = {2026},
volume = {7},
number = {2},
doi = {10.46966/msjar.v7i2.413}
}
EUVIMED